Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180027/S014

FRED X System

Microvention, Inc. · Decision date Sep 18, 2025

FDA DECISIONP180027/S014

What did the FDA approve?

FDA records P180027/S014 as a supplement to PMA P180027, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 18, 2025.

FDA approval order statement

Approval of claims regarding reduced acute material thrombogenicity supported by in-vitro testing on a proprietary device surface modification.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Sep 18, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P180027/S014
Regulatory pathway
PMA supplement
Product code
OUT
Decision code
APPR
Decision date
Sep 18, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Intracranial aneurysm flow diverter.

Product code
OUT
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180027/S014 received

    Application receipt date recorded by FDA.

  2. P180027/S014 · FDA decision

    Real-Time Process

  3. P180027/S012 · Related supplement

    Flow Re-Direction Endoluminal Device (FRED) X System

  4. P180027/S013 · Related supplement

    Flow Re-Direction Endoluminal Device (FRED) System

Timeline entries are records held by MedtechLedger for P180027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180027

Product / regulatory recordCompanyPathwayDecision dateSource
Microvention, Inc.PMA supplementSep 20, 2025FDA
Microvention, Inc.PMA supplementNov 2, 2025FDA

Explore the linked device profile

Other records with product code OUT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Microvention, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
35 Enterpricse, Aliso Viejo, CA, 92656

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records